Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 17 of 17 for “"EML4-ALK"”.

  1. Evolution of Targeted Therapy Resistance in EML4-ALK Positive Non-Small Cell Lung Cancer

    … we investigated the evolution of resistance to EML4-ALK inhibitors in non-small cell lung cancer (NSCLC) and demonstrated that resistance evolves gradually, from unique pre-treatment sub-populations, as multiple resistance mechanisms accumulate in a Darwinian fashion. Despite accumulating …

    usf Repository record for Evolution of Targeted Therapy Resistance in EML4-ALK Positive Non-Small Cell Lung Cancer (opens in a new tab)

  2. NOVEL THERAPEUTIC STRATEGIES IN LUNG CANCERSTRONG BIOLOGICAL BIAS FOR ALK INTRON 19 BREAKPOINTS IN NON-SMALL LUNG CANCER

    … therapy with tyrosine kinase inhibitors. EML4-ALK translocations are detected in 4-8 % of NSCLC and define a specific subtype of oncogene-driven lung cancer. While different EML4-ALK variants are defined by different breakpoints in the EML4 gene, most frequently located in intron 6 or 13, …

    catania Repository record for NOVEL THERAPEUTIC STRATEGIES IN LUNG CANCERSTRONG BIOLOGICAL BIAS FOR ALK INTRON 19 BREAKPOINTS IN NON-SMALL LUNG CANCER (opens in a new tab)

  3. Belizatinib is a potent inhibitor for non-small cell lung cancers driven by different variants of EML4-ALK fusion proteins carrying L1196M-mutations

    Structural fusions of EML4 with ALK kinase might lead to signaling abnormalities that drive NSCLC. Although approved specific ALK inhibitors have led to excellent initial responses in ALK positive NSCLC patients, acquired resistance to these inhibitors due to the occurrence of mutations is a major …

    lmu-germany Repository record for Belizatinib is a potent inhibitor for non-small cell lung cancers driven by different variants of EML4-ALK fusion proteins carrying L1196M-mutations (opens in a new tab)

  4. Cost-utility analysis of EML4-ALK fusion testing followed by treatment with crizotinib in patients with Non-Small Cell Lung Cancer (NSCLC)

    … by Pfizer, Inc. demonstrated that crizotinib (Xalkori, Pfizer, Inc.) offers significant improvement in clinical outcomes as a second line therapy for the treatment of EML4-ALK fusion–positive non-small-cell lung cancer (NSCLC). In 2013, the US Food and Drug Administration (FDA) approved …

    washington Repository record for Cost-utility analysis of EML4-ALK fusion testing followed by treatment with crizotinib in patients with Non-Small Cell Lung Cancer (NSCLC) (opens in a new tab)

  5. Elucidation of Molecular Mechanisms Underlying Novel Multi-Targeted Therapy Strategies for

    EML4-ALK fusion non-small cell lung cancer (NSCLC) represents a distinct subset of lung cancers that possesses unique molecular and clinical features, paving the way for targeted therapeutic interventions. Despite the promise of ALK-directed therapies, challenges such as metastasis at the time of …

    usf Repository record for Elucidation of Molecular Mechanisms Underlying Novel Multi-Targeted Therapy Strategies for (opens in a new tab)

  6. Dissecting mechanisms and consequences of oncogenic RTK fusion signaling

    … optogenetics and live-cell imaging to find that EML4-ALK, an oncogenic fusion present in 5-7% of non-small cell lung cancers, suppress transmembrane RTK signaling by sequestering RTK adapter proteins including GRB2 and SOS1. Furthermore, ALK inhibition, while suppressing oncogenic signaling, …

    penn Repository record for Dissecting mechanisms and consequences of oncogenic RTK fusion signaling (opens in a new tab)

  7. Structural and Biochemical Characterization of <em>Epigenetic</em> and <em>Fusion Tyrosine Kinase</em> Cancer Targets for Drug Development

    … The second class of protein under investigation, EML4-ALK, is a fusion tyrosine kinase (FTK). Fusion tyrosine kinases (FTKs) have been identified as an oncogene in 5–10% of the overall population in non-small cell lung cancer (NSCLC), which is a major cause of cancer-related mortalities. FTKs …

    usf Repository record for Structural and Biochemical Characterization of <em>Epigenetic</em> and <em>Fusion Tyrosine Kinase</em> Cancer Targets for Drug Development (opens in a new tab)

  8. Using next generation sequencing to detect clinically relevant oncogene mutations in lung cancer

    … identifying targetable mutations in the EGFR and ALK genes in lung cancer. Methods: DNA and RNA from 38 formalin fixed paraffin embedded lung cancer samples (37 non-small cell lung cancer (NSCLC) and one small cell lung cancer (SCLC)) archived in Diagnostic Services Manitoba were collected and …

    manitoba Repository record for Using next generation sequencing to detect clinically relevant oncogene mutations in lung cancer (opens in a new tab)

  9. Multi-'omics comparison of lung cancers from current and never smokers

    … select specific mutations (e.g. EGFR, KRAS, EML4-ALK), suggesting they are distinct diseases. Thus, we hypothesize that lung tumours of CS and NS exhibit disparate patterns of molecular alterations on a genome wide scale, reflecting the assumption that they develop through the differential …

    ubc Repository record for Multi-'omics comparison of lung cancers from current and never smokers (opens in a new tab) Download PDF for Multi-'omics comparison of lung cancers from current and never smokers (opens in a new tab)

  10. The role of CD74 in the development of resistance to tyrosine kinase inhibitors in ROS1- and ALK-fusion non-small cell lung cancer

    … cells emerge is limited, especially in ROS1- and ALK-rearrangement NSCLCs. In a prior study, single-cell RNA-sequencing (scRNA-seq) analysis was performed and detected CD74 as a potential DTP candidate gene that may allow cells to enter a DTP state in NSCLC harboring an EGFR¬ mutation. In this …

    bu Repository record for The role of CD74 in the development of resistance to tyrosine kinase inhibitors in ROS1- and ALK-fusion non-small cell lung cancer (opens in a new tab)

  11. Discovery and Development of Predictive Biomarkers for the Personalization of Pemetrexed Therapy in Non-Small Cell Lung Cancer

    … more frequent in sensitive lines, and EML4/ALK adenocarcinomas conferred sensitivity to pemetrexed, consistent with recent clinical findings. In order to test whether the in vitro pemetrexed response phenotypes could be recapitulated in vivo, doses from 26.6 mg/kg up to 1000 mg/kg …

    utswmed Repository record for Discovery and Development of Predictive Biomarkers for the Personalization of Pemetrexed Therapy in Non-Small Cell Lung Cancer (opens in a new tab)

  12. Pre-clinical rationale for new indications and novel combinations of the tyrosine kinase inhibitor neratinib in cancer

    … like dasatinib (multi-kinase), crizotinib (ALK) and sotorasib (KRASG12C) was investigated in vitro in HER-driven gastroesophageal, lung, pancreatic and head and neck cancer cell lines by proliferation, apoptosis, migration assays and signalling analysis. Neratinib-sotorasib was further …

    dcu Download PDF for Pre-clinical rationale for new indications and novel combinations of the tyrosine kinase inhibitor neratinib in cancer (opens in a new tab) Embargoed until 2029-02-05

  13. Procaspase-3 activation as a strategy to overcome resistance to targeted anticancer therapies

    … in the MAPK pathway. Besides BRAFV600E, EGFR, ALK, ABL, and RAS are oncogenes that are frequently altered in this pathway. While many mutant oncogenes have been identified, only mutations or alterations to EGFR, ALK, and ABL kinases can be targeted clinically by specific kinase inhibitions to …

    uiuc Repository record for Procaspase-3 activation as a strategy to overcome resistance to targeted anticancer therapies (opens in a new tab)